HOLX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

1.07B

+5.06%

1.097

+6.5%

1.05B

+4.64%

1.099

+6.66%

1.07B

+4.65%

1.153

+6.72%

Estimates Revision

The market is revising Upward the revenue expectations for Hologic, Inc. (HOLX) for FY2026, with the revenue forecasts being adjusted by 0.37% over the past three months. During the same period, the stock price has changed by 9.11%.

Revenue Estimates for FY2026

Revise Upward

+0.37%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+0.84%

In Past 3 Month

Stock Price

Go Up

+9.11%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast HOLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOLX is 79.22 USD with a low forecast of 76.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

10 Hold

0 Sell

Hold

Current: 0.000

Low

76.00

Averages

79.22

High

94.00

Current: 0.000

Low

76.00

Averages

79.22

High

94.00

Evercore ISI

Outperform -> In Line

downgrade

$79 -> $78

2026-01-05

New

Reason

Evercore ISI

Price Target

$79 -> $78

2026-01-05

New

downgrade

Outperform -> In Line

Reason

Evercore ISI downgraded Hologic to In Line from Outperform with a price target of $78, down from $79.

BNP Paribas Exane

Outperform -> Neutral

downgrade

$79

2025-11-21

Reason

BNP Paribas Exane

Price Target

$79

2025-11-21

downgrade

Outperform -> Neutral

Reason

BNP Paribas Exane downgraded Hologic to Neutral from Outperform with a $79 price target.

Morgan Stanley

Equal Weight

maintain

$69 -> $76

2025-11-10

Reason

Morgan Stanley

Price Target

$69 -> $76

2025-11-10

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Hologic (HOLX) to $76 from $69 and keeps an Equal Weight rating on the shares after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share. The firm views the proposed acquisition price as "a fair valuation" and doesn't expect any barriers to the transaction closing in the first half of 2026, the analyst tells investors.

Mizuho

Outperform -> Neutral

downgrade

$78

2025-10-23

Reason

Mizuho

Price Target

$78

2025-10-23

downgrade

Outperform -> Neutral

Reason

Mizuho downgraded Hologic (HOLX) to Neutral from Outperform with a $78 price target after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.

Stephens

Overweight -> Equal Weight

downgrade

$78 -> $76

2025-10-22

Reason

Stephens

Price Target

$78 -> $76

2025-10-22

downgrade

Overweight -> Equal Weight

Reason

Stephens downgraded Hologic (HOLX) to Equal Weight from Overweight with a price target of $76, down from $78, after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share. The deal is in line with the firm's expectations and "seems fair based on our outlook," the analyst tells investors.

JPMorgan

Overweight -> Neutral

downgrade

$78

2025-10-21

Reason

JPMorgan

Price Target

$78

2025-10-21

downgrade

Overweight -> Neutral

Reason

JPMorgan downgraded Hologic (HOLX) to Neutral from Overweight with a $78 price target after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.

Valuation Metrics

The current forward P/E ratio for Hologic Inc (HOLX.O) is 16.35, compared to its 5-year average forward P/E of 17.76. For a more detailed relative valuation and DCF analysis to assess Hologic Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

17.76

Current PE

16.35

Overvalued PE

21.10

Undervalued PE

14.43

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

13.06

Current EV/EBITDA

12.13

Overvalued EV/EBITDA

15.17

Undervalued EV/EBITDA

10.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.28

Current PS

3.88

Overvalued PS

4.81

Undervalued PS

3.74

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 4616.24% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

HOLX News & Events

Events Timeline

No data

News

8.5

01-07PRnewswire

PinnedHologic, Inc. to be Sold for $76 per Share to Blackstone and TPG

8.5

01-08PRnewswire

Hologic to Sell to Blackstone and TPG for $76 per Share

3.5

2025-12-31Newsfilter

Oncolytics Biotech Achieves 33% Response Rate with Pelareorep in KRAS-Mutant Colorectal Cancer

People Also Watch

Frequently Asked Questions

What is Hologic Inc (HOLX) stock price today?

The current price of HOLX is 74.87 USD — it has decreased -0.01 % in the last trading day.

What is Hologic Inc (HOLX)'s business?

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

What is the price predicton of HOLX Stock?

What is Hologic Inc (HOLX)'s revenue for the last quarter?

Hologic Inc revenue for the last quarter amounts to 1.05B USD, increased 6.23 % YoY.

What is Hologic Inc (HOLX)'s earnings per share (EPS) for the last quarter?

Hologic Inc. EPS for the last quarter amounts to 0.83 USD, increased 9.21 % YoY.

What changes have occurred in the market's expectations for Hologic Inc (HOLX)'s fundamentals?

How many employees does Hologic Inc (HOLX). have?

Hologic Inc (HOLX) has 7070 emplpoyees as of January 10 2026.

What is Hologic Inc (HOLX) market cap?

Today HOLX has the market capitalization of 16.70B USD.